XORTX Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$1.08next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly864.5KTarget: Sufficient capital to fund clinical trials and operations
Accumulated Deficit Quarterly23.8MTarget: Reduction through future commercialization and licensing revenues
Watch Items
- IND Submission for XRx-026 (Gout Program)Trigger: Filing of Investigational New Drug application with the FDAAction: Initiate the proposed two-part bridging clinical study XRX-OXY-102
- XRX-OXY-102 Clinical Trial InitiationTrigger: Favorable FDA discussions and IND clearanceAction: Begin Part 1 (steady-state pharmacokinetics of XORLO) and Part 2 (therapeutic equivalence versus allopurinol)
- Going Concern Material UncertaintyTrigger: Cash runway falling below critical operational thresholdsAction: Secure additional dilutive or non-dilutive financing, or establish strategic partnerships
Research as of 20 Jun 2026